LncRNA LINC00511 Acts As an Oncogene in Colorectal Cancer Via Sponging MiR-29c-3p to Upregulate NFIA

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Feb 4

PMID 33536761

Citations 15

Authors

Yu Hu

Ying Zhang

Meng Ding

Ruisi Xu

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer (CRC), characterized by high mortality and incidence rate, is one of the most common types of rectum tumors in the gastrointestinal tract worldwide. An increasing number of investigations indicated that long noncoding RNAs (lncRNAs) have been implicated in the growth of a wide range of cancers. Although it has obtained general acceptance that lncRNA LINC00511 plays a significant role in numerous cancers, the regulatory mechanism of LINC00511 in CRC still needs to be explored.

Materials And Methods: Bioinformatics analysis and a wide range of experiments of sphere formation assay, cell proliferation assay, RT-qPCR, colony formation assay, Transwell assay and Western blot assays investigated the function and mechanism of LINC00511 in CRC tissues and cells.

Results: Our results manifested that the expression level of LINC00511 was obviously upregulated in CRC tissues and cells and it accelerated CRC development through facilitating cell proliferation, metastasis and stemness. Molecular mechanism exploration uncovered that LINC00511 acted as a ceRNA competing with to bind with miR-29c-3p. Through rescue experiments, we discovered that NFIA upregulation partly counteracted the inhibitive effect induced by LINC00511 silencing on CRC progression.

Conclusion: These results revealed that LINC00511 participated in the progression of CRC by targeting the LINC00511/miR-29c-3p/ axis, indicating that LINC00511 may be a potential therapeutic target for CRC treatment.

Citing Articles

PSAT1 promotes the progression of colorectal cancer by regulating Hippo-YAP/TAZ-ID1 axis via AMOT.

Tang M, Song K, Xie D, Yuan X, Wang Y, Li Z Mol Cell Biochem. 2024; .

PMID: 39739271 DOI: 10.1007/s11010-024-05194-8.

The emerging roles of LINC00511 in breast cancer development and therapy.

Zhao L, Biswas S, Li Y, Sooranna S Front Oncol. 2024; 14:1429262.

PMID: 39206156 PMC: 11349568. DOI: 10.3389/fonc.2024.1429262.

YY1-induced lncRNA00511 promotes melanoma progression via the miR-150-5p/ADAM19 axis.

Chen Y, Fu X, Guo H, Fu X, Shi K, Gao T Am J Cancer Res. 2024; 14(2):809-831.

PMID: 38455406 PMC: 10915319.

The Intergenic Type LncRNA (LINC RNA) Faces in Cancer with In Silico Scope and a Directed Lens to LINC00511: A Step toward ncRNA Precision.

Eldash S, Sanad E, Nada D, Hamdy N Noncoding RNA. 2023; 9(5).

PMID: 37888204 PMC: 10610215. DOI: 10.3390/ncrna9050058.

A review on the role of LINC00511 in cancer.

Ghafouri-Fard S, Safarzadeh A, Hussen B, Taheri M, Ayatollahi S Front Genet. 2023; 14:1116445.

PMID: 37124625 PMC: 10140539. DOI: 10.3389/fgene.2023.1116445.

References

Liu R, Wang L, Gan T, Pan T, Huang J, Bai M . Long noncoding RNA LINC00511 promotes cell growth and invasion in triple-negative breast cancer by interacting with Snail. Cancer Manag Res. 2019; 11:5691-5699. PMC: 6600316. DOI: 10.2147/CMAR.S203455. View

Liu L, Zhu Y, Liu A, Feng Y, Chen Y . Long noncoding RNA LINC00511 involves in breast cancer recurrence and radioresistance by regulating STXBP4 expression via miR-185. Eur Rev Med Pharmacol Sci. 2019; 23(17):7457-7468. DOI: 10.26355/eurrev_201909_18855. View

DAngelo B, Benedetti E, Cimini A, Giordano A . MicroRNAs: A Puzzling Tool in Cancer Diagnostics and Therapy. Anticancer Res. 2016; 36(11):5571-5575. DOI: 10.21873/anticanres.11142. View

Yu C, Zhang F . LncRNA AC009022.1 enhances colorectal cancer cells proliferation, migration, and invasion by promoting ACTR3B expression via suppressing miR-497-5p. J Cell Biochem. 2019; 121(2):1934-1944. DOI: 10.1002/jcb.29428. View

Jiang L, Xie X, Ding F, Mei J, Bi R . Silencing LINC00511 inhibits cell proliferation, migration, and epithelial-mesenchymal transition via the PTEN-AKT-FOXO1 signaling pathway in lung cancer. Biochem Cell Biol. 2019; 99(2):1-8. DOI: 10.1139/bcb-2018-0364. View

Chen Y, Zhang B, Jin Y, Wu Q, Cao L . MiR-27b targets PI3K p110α to inhibit proliferation and migration in colorectal cancer stem cell. Am J Transl Res. 2019; 11(9):5988-5997. PMC: 6789227. View

Wu H, Zhang W, Wu Z, Liu Y, Shi Y, Gong J . miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma. Cell Death Dis. 2019; 10(2):48. PMC: 6362005. DOI: 10.1038/s41419-018-1281-7. View

Kleffel S, Schatton T . Tumor dormancy and cancer stem cells: two sides of the same coin?. Adv Exp Med Biol. 2012; 734:145-79. DOI: 10.1007/978-1-4614-1445-2_8. View

Wu X, Chen H, Zhang G, Wu J, Zhu W, Gu Y . MiR-212-3p inhibits cell proliferation and promotes apoptosis by targeting nuclear factor IA in bladder cancer. J Biosci. 2019; 44(4). View

10.

Dong X, Song Y, Lu Y, Hu Y, Liu P, Zhang L . Sanguinarine inhibits the proliferation of BGC-823 gastric cancer cells via regulating miR-96-5p/miR-29c-3p and the MAPK/JNK signaling pathway. J Nat Med. 2019; 73(4):777-788. DOI: 10.1007/s11418-019-01330-7. View

11.

Huang L, Jiang X, Kang P, Wang Z, Leng K, Ji D . Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma. Cancer Manag Res. 2019; 11:7739-7749. PMC: 6699498. DOI: 10.2147/CMAR.S207801. View

12.

Lin C, Li H, Liu Y, Kuo P, Wang W, Lin F . High-CLDN4 ESCC cells harbor stem-like properties and indicate for poor concurrent chemoradiation therapy response in esophageal squamous cell carcinoma. Ther Adv Med Oncol. 2019; 11:1758835919875324. PMC: 6767752. DOI: 10.1177/1758835919875324. View

13.

Murphy N, Moreno V, Hughes D, Vodicka L, Vodicka P, Aglago E . Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Mol Aspects Med. 2019; 69:2-9. DOI: 10.1016/j.mam.2019.06.005. View

14.

Kong F, Lv Y, Yao H, Zhang H, Zhou Y, Liu S . LncRNA PCAT6 promotes occurrence and development of ovarian cancer by inhibiting PTEN. Eur Rev Med Pharmacol Sci. 2019; 23(19):8230-8238. DOI: 10.26355/eurrev_201910_19132. View

15.

Yu X, Wang M, Zuo J, Wahafu A, Mao P, Li R . Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Life Sci. 2019; 236:116917. DOI: 10.1016/j.lfs.2019.116917. View

16.

Chen H, Zong J, Wang S . LncRNA GAPLINC promotes the growth and metastasis of glioblastoma by sponging miR-331-3p. Eur Rev Med Pharmacol Sci. 2019; 23(1):262-270. DOI: 10.26355/eurrev_201901_16772. View

17.

Shi J, Li J, Yang S, Hu X, Chen J, Feng J . LncRNA SNHG3 is activated by E2F1 and promotes proliferation and migration of non-small-cell lung cancer cells through activating TGF-β pathway and IL-6/JAK2/STAT3 pathway. J Cell Physiol. 2019; 235(3):2891-2900. DOI: 10.1002/jcp.29194. View

18.

Zhao X, Liu Y, Li Z, Zheng S, Wang Z, Li W . Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2017; 22(1):655-667. PMC: 5742682. DOI: 10.1111/jcmm.13351. View

19.

Wang H, Fu L, Wei D, Wang B, Zhang C, Zhu T . MiR-29c-3p Suppresses the Migration, Invasion and Cell Cycle in Esophageal Carcinoma via CCNA2/p53 Axis. Front Bioeng Biotechnol. 2020; 8:75. PMC: 7044414. DOI: 10.3389/fbioe.2020.00075. View

20.

Xu W, Zhou G, Wang H, Liu Y, Chen B, Chen W . Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer. Int J Cancer. 2019; 146(10):2901-2912. DOI: 10.1002/ijc.32747. View